Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
18.86
+0.89 (4.92%)
Aug 13, 2025, 4:00 PM - Market closed
Viridian Therapeutics Employees
Viridian Therapeutics had 143 employees as of December 31, 2024. The number of employees increased by 49 or 52.13% compared to the previous year.
Employees
143
Change (1Y)
49
Growth (1Y)
52.13%
Revenue / Employee
$2,133
Profits / Employee
-$1,928,273
Market Cap
1.54B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VRDN News
- 6 days ago - These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results - Benzinga
- 8 days ago - Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - Business Wire
- 10 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments - Business Wire
- 6 weeks ago - Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Viridian Therapeutics: The Song Remains The Same - Seeking Alpha
- 2 months ago - Viridian Therapeutics to Participate in Upcoming June Investor Conferences - Business Wire
- 3 months ago - Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - Business Wire